BioSpace News Archive

Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Blueprint Medicines Corporation as a specialty pharmacy provider for AYVAKITTM (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Onxeo S.A.,, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response, in particular against rare or resistant cancers, announces the publication of its shareholder letter.

The Chief Public Health Officer and Government of Canada officials will hold a media availability to provide information on a novel coronavirus.

Lexicon Pharmaceuticals, Inc., announced that data from a poster highlighting XERMELO® will be presented at the American Society for Clinical Oncology 2020 Symposium.

Avivagen Inc., a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to provide an update on the status of its previously announced non-brokered private placement of units at an issue price of $0.50 per Unit.

Neurocrine Biosciences, Inc. announced that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020.

Cipher Pharmaceuticals Inc. announced the Company received a Notice of Termination from Bausch Health in connection with the License, Development and Commercialization Agreement of Trulance®.